HA
Hazim Ababneh
Research areas: Medicine · Pathology and Forensic Medicine · Lymphoma Diagnosis and Treatment · CAR-T cell therapy research · Cutaneous lymphoproliferative disorders research
0000-0002-0393-9852
Employment
Employment history is unavailable.
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (22)
- Outcomes of combined bispecific antibody and radiation therapy in relapsed/refractory hematologic malignancies Save
- 5-5-5 ABRT (Dose of 5 Gy per Fraction for up to 5 Fractions Over 5 Weeks Adaptive Bridging Radiation Therapy)—Artificial Intelligence Enters the CAR (-T) (Chimeric Antigen Receptor-T) in Relapsed/Refractory Large B Cell Lymphoma Save
- Breaking Traditions: Evaluating Single Fraction Radiation in Indolent Lymphoma Save
- Post‐CAR T‐Cell Therapy Failure Metabolic Parameters Predict Survival and Response in Large B‐Cell Lymphoma Save
- Radiotherapy as a bridging strategy for patients with relapsed or refractory large B‐cell lymphoma undergoing CAR T‐cell therapy Save
- Metabolic parameters predict survival and toxicity in chimeric antigen receptor T‐cell therapy‐treated relapsed/refractory large B‐cell lymphoma Save
- Radiation therapy as bridging and salvage strategy among patients with secondary central nervous system lymphoma undergoing CD19‐targeted chimeric antigen receptor T‐cell therapy Save
- Radiation therapy for patients with relapsed or refractory mantle cell lymphoma undergoing CD19‐targeted chimeric antigen receptor T‐cell therapy Save
- Radiation therapy as bridging and salvage strategy in patients with relapsed or refractory multiple myeloma undergoing BCMA-targeted CAR T-cell therapy Save
- Side effects of COVID-19 vaccinations in patients treated for breast cancer Save
- Leaving Lytic Lesions—Is There New Role for Radiation in Multiple Myeloma in the CAR T Era? Save
- Supportive Care Needs Assessment for Cancer Survivors at a Comprehensive Cancer Center in the Middle East: Mending the Gap Save
- ABCL-043 Prognostic Factors for High-Grade B Cell Lymphoma Patients Treated With Commercial CD19-Targeted CAR T-Cell Therapy Save
- ABCL-044 Clinical Outcomes of Commercial CD19-Targeted CAR T-Cell Therapy in Patients With Secondary Central Nervous System Lymphoma Save
- ABCL-242 Definition of Bulky Disease in Early-Stage Diffuse Large B-Cell Lymphoma on Longitudinal and Axial Planes Save
- Assessing the role of radiotherapy in patients with refractory or relapsed high-grade B-cell lymphomas treated with CAR T-cell therapy Save
- Early surgical and oncological outcomes during adoption of a single port VATS lung resection in a tertiary cancer center: a retrospective analysis Save
- Elective surgery system strengthening: development, measurement, and validation of the surgical preparedness index across 1632 hospitals in 119 countries Save
- Impact of the COVID-19 pandemic on patients with paediatric cancer in low-income, middle-income and high-income countries: a multicentre, international, observational cohort study Save
- Primary radiation therapy for advanced-stage laryngeal cancer: A laryngo-esophageal dysfunction disease-free survival Save